Omeros Reports the US FDA's Acceptance and Priority Review of BLA for Narsoplimab (OMS721) to Treat HSCT-TMA
Shots:
- The US FDA has accepted the BLA and granted the PR with an anticipated PDUFA date as Jul 17- 2021
- The BLA filing marks the milestone on the path to commercialization of narsoplimab
- Narsoplimab is an investigational mAb targeting MASP-2 has received the US FDA’s BTD and ODD to the FDA for each of HSCT-TMA and IgA nephropathy
Ref: Businesswire | Image: Omeros
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
